Differences Between Community and Academic Settings Regarding Biomarker Testing Practices in Metastatic Melanoma
Source: OncLive, November 2023
The panelists emphasize the importance of obtaining tissue for BRAF-mutation testing and dedicated tissue tracking in patients with metastatic melanoma, with immunohistochemistry followed by confirmatory next-generation sequencing, and discuss the promise of liquid biopsies like ctDNA as a future biomarker tracking modality.
